Ursodeoxycholic acid
- Generic Name
- Ursodeoxycholic acid
- Brand Names
- Reltone, Urso, Urso Forte
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40O4
- CAS Number
- 128-13-2
- Unique Ingredient Identifier
- 724L30Y2QR
- Background
Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool. UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years. UDCA was first characterized in the bile of the Chinese black bear and is form...
- Indication
Ursodeoxycholic acid is indicated for the treatment of patients with primary biliary cholangitis.
It is used for the short-term treatment of radiolucent, noncalcified gallbladder stones in patients selected for elective cholecystectomy. It is also used to prevent gallstone formation in obese patients experiencing rapid weight loss.
- Associated Conditions
- Gallstones, Primary Biliary Cholangitis
- Associated Therapies
- -
Ursodeoxycholic Acid in Chronic Heart Failure
- Conditions
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2009-10-09
- Lead Sponsor
- National Heart and Lung Institute
- Registration Number
- NCT00285597
- Locations
- 🇬🇧
National Heart and Lung Institute, London, United Kingdom
UDCA for Symptomatic Gallstone Disease
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2006-07-27
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 180
- Registration Number
- NCT00161083
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients
- Conditions
- Interventions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2009-07-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 90
- Registration Number
- NCT00134758
- Locations
- 🇫🇷
Saint-Antoine Hospital, Paris, France
Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00062023
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Trial of High-dose Urso in Primary Sclerosing Cholangitis
- Conditions
- Interventions
- First Posted Date
- 2003-04-22
- Last Posted Date
- 2021-05-03
- Target Recruit Count
- 150
- Registration Number
- NCT00059202
- Locations
- 🇺🇸
St. Louis University, Saint Louis, Missouri, United States
🇺🇸Medical College of Virginia, Richmond, Virginia, United States
🇺🇸University of Washington, Seattle, Washington, United States
Lithotripsy for the Treatment of Gallstones
- Conditions
- First Posted Date
- 2002-08-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Medstone International
- Target Recruit Count
- 184
- Registration Number
- NCT00042549
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸Virgina Commonwealth University, Richmond, Virginia, United States
Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 315
- Registration Number
- NCT00004784
Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 90
- Registration Number
- NCT00004748
Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 39
- Registration Number
- NCT00004441
- Locations
- 🇺🇸
Children's Hospital of Denver, Denver, Colorado, United States
🇺🇸Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States
🇮🇹University of Milan, Milan, Italy
Study of Bile Acids in Patients With Peroxisomal Disorders
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 25
- Registration Number
- NCT00004442
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.